Gain Therapeutics has set up a clinical advisory board made up of leading Parkinson’s experts in genetics, biomarkers, and trial design to guide the advancement of GT-02287, its investigational therapy for Parkinson’s disease. The advisory board will collaborate with Gain’s leadership to guide GT-02287 through its potential Phase…
News
A research project that’s designed to help improve communication for people with Parkinson’s disease by focusing on listener training has been awarded a $2.6 million, five-year grant from the National Institutes of Health (NIH). The funding will help researchers implement a structured listener training program and test its effectiveness in…
The first patient in a Phase 2 clinical study testing BIA 28-6156 — a small molecule in the pipeline at Bial for treating Parkinson’s disease in people with mutations in the GBA1 gene — has completed the full dose regimen, the company announced. The goal of the study,…
Mytos and Aspen Neuroscience are teaming up to automate the manufacture of autologous dopaminergic neuronal precursor cells (DNPCs) for ANPD001, Aspen’s experimental cell therapy program for Parkinson’s disease. As part of the agreement, Aspen will integrate Mytos’ iDEM automated cell culture technology into its new manufacturing…
Actor Michael J. Fox has received the Presidential Medal of Freedom from U.S. President Joe Biden for his work as an advocate and founder of The Michael J. Fox Foundation for Parkinson’s Research. Awarded at the White House, the Presidential Medal of Freedom is the highest honor civilians can…
The American Parkinson Disease Association (APDA) has announced that it will host its third annual, free, virtual conference for people with Parkinson’s disease and their caregivers on Feb. 19-20. The program is scheduled to run from 12 p.m. to 4 p.m. ET each day. Tailored to “educate, empower…
Treatment with Vyalev (foscarbidopa and foslevodopa) eased motor symptoms and sleep disturbances in a 50-year-old man with Parkinson’s disease and a history of dream enactment behavior, according to a case report from Japan. Dream enactment behavior is a sign of rapid eye movement (REM) sleep disorder, in which…
A new screening method may shed light on the interactions between genetic variants that increase the risk of Parkinson’s disease, providing potential avenues for improving risk prediction and personalized care, a study found. The tool, Variant-variant Interaction through Variable Thresholds (VARI3), is designed to detect and interpret how genetic…
People who develop Parkinson’s disease begin turning more slowly while walking — often using wider turning arcs — nearly a decade before diagnosis, according to a long-term study involving wearable movement sensors. “This research opens a vital window for early intervention,” Brook Galna, an associate professor from Murdoch University…
The motor cortex, a brain region responsible for movement control, becomes disconnected in levodopa-induced dyskinesia (LID), the uncontrolled movements that occur as a side effect of the drug levodopa in Parkinson’s disease, a study found. Ketamine, an anesthetic used to alleviate LID, was found to restore the motor cortex’s…
Recent Posts